Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Rhea-AI Summary

Gb Sciences has announced promising results for its cannabinoid-containing therapy aimed at treating cytokine release syndrome (CRS), a severe complication of COVID-19. The research, conducted by Michigan State University, indicated that complex mixtures of synthetic cannabinoids effectively reduced biomarkers associated with CRS and showed potential for use in related conditions. As the Omicron variant emerges, Gb Sciences aims to accelerate development of this therapy, which targets the immune response rather than the virus itself. The company holds several patents and is developing multiple drug candidates.

Positive

• Promising preclinical results for cannabinoid-containing therapy targeting CRS.
• Research indicates effectiveness against biomarkers linked to severe COVID-19 complications.
• Accelerated development plans in response to the emergence of the Omicron variant.
• Company holds multiple patents and has a diverse drug development pipeline.

Negative

• None.

Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies

LAS VEGAS, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With reports of the arrival of the Omicron variant of the coronavirus in multiple countries, the Gb Sciences team plans to move quickly through the development stages for this novel CRS therapy. 

"COVID variants are not going away anytime soon, and they will continue to cause health complications, particularly in unvaccinated individuals and older populations," said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. "The need for effective treatments is growing. We are excited about the progress we have been making with our potential CRS treatment, which in essence can reset the body's immune system. This strategy works regardless of the variant because it provides relief by targeting our human immune response to a virus, but it's not tied to the virus itself."

Using its AI-driven drug discovery platform, Gb Sciences developed cannabinoid-containing complex mixtures (CCCM) designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by the COVID-19 virus, while preserving the immune functions and cytokines necessary to fight the disease.

The study, completed by researchers at Michigan State University in August 2021, found that specific formulations of the CCCMs reduced cytokine release syndrome biomarkers. Mixtures of multiple synthetic molecules from cannabinoid plants performed better than single molecules alone, and the ratios of those molecules also influenced results, the company reported. 

The preclinical data indicates that the CCCMs may be effective anti-inflammatory therapies for CRS and other conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS)-- all leading causes of death in COVID-19 patients.

To learn more as to how Gb Sciences is leveraging biopharma technology and research to develop cannabinoid-containing complex mixtures and advance innovative COVID-19 treatments, please visit gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-based research and biopharma drug development company creating patented, disease-targeted formulations of plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices.

Gb Sciences' novel drug discovery platform has yielded three issued U.S. patents, as well as 8 U.S. and 39 international pending patent applications. In its drug development pipeline, the company has four preclinical-stage programs, and its lead Parkinson's disease therapeutic program is being prepared for a First-in-Human clinical trial. In addition to Parkinson's disease, GB Sciences is developing therapeutics for COVID-related cytokine release syndrome (CRS), chronic pain, anxiety, depression, Mast Cell Activation Syndrome (MCAS), and heart failure. GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Contact Information

Alexis Quintal
alexis@newswire.com

Related Images

Image 1: Gb Sciences, Inc

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Gb Sciences, Inc

FAQ

What are the latest developments from Gb Sciences regarding CRS treatment?

Gb Sciences reported positive preclinical results for its cannabinoid-containing therapy aimed at treating cytokine release syndrome, indicating effectiveness in reducing biomarkers associated with the condition.

How is Gb Sciences responding to the Omicron variant of COVID-19?

Gb Sciences plans to accelerate the development of its novel therapy for cytokine release syndrome as the Omicron variant poses new health challenges.

What is the significance of Gb Sciences' cannabinoid-containing complex mixtures?

The cannabinoid-containing complex mixtures developed by Gb Sciences have shown potential in reducing inflammation and may be effective in treating CRS and related conditions.

Which research institution conducted the study for Gb Sciences' CRS treatment?

The study for Gb Sciences' cytokine release syndrome treatment was completed by researchers at Michigan State University.

What is the patent status of Gb Sciences' drug development?

Gb Sciences holds three issued U.S. patents and has several pending applications related to its drug development pipeline.